BREO™ ELLIPTA™ Receives Regulatory Approval in U.S.Skyepharma eligible for royalties of up to £6 million per annumLONDON, UK, 13 May, 2013 - Skyepharma PLC (LSE: SKP), the expert oral and inhalation drug delivery company, announces that the United States ...
[Published Best Invest - May 13 2013]